key: cord-0937263-m3wffq2f
authors: Routsolias, Joanne C.; Mycyk, Mark B.
title: The COVID-19 Pandemic Continues to Challenge Patients In Need of Buprenorphine for Opioid Use Disorder
date: 2021-02-05
journal: J Emerg Nurs
DOI: 10.1016/j.jen.2021.01.011
sha: a4b43a3fef0b6c46f27d9fb5a9c1fb6437fe7325
doc_id: 937263
cord_uid: m3wffq2f

nan

We thank Dr. Strout and colleagues for their well-written and comprehensive review 3 "Understanding ED Buprenorphine Initiation For Opioid Use Disorder: A Guide For Emergency 4 Nurses" in this journal [1] . Patients with opioid use disorder (OUD) are vulnerable, and we 5 think their review should be read by all involved in clinical ED care, not just by nurses as 6 mentioned in their title. We write to highlight one area not mentioned in their well-written review: how the prolonged 9 COVID-19 pandemic has challenged treatment of patients with OUD and their access to 10 buprenorphine. The example at our institution is generalizable to others and important for all 11 to recognize as the pandemic continues. The Illinois state "shelter-in-place" order took effect on 3/21/20. Compared to the three-month 24 period prior to that order, in the following three months the total number of prescriptions prescriptions originating from the ED. Prior to the pandemic, patients were referred directly to 28 clinic or a treatment center from the ED, but if there were delays to immediate referral (e.g., 29 night, weekend, treatment center at capacity) our ED provided 3 days of buprenorphine-30 naloxone with linkage to in-person treatment during that time. Now during the pandemic, our 31 ED procedure is to prescribe a full 30-day course with the understanding that linkage to an 32 addiction specialist may not happen during that period. We know medication alone is not 

Understanding ED Buprenorphine Initiation For Opioid 57 Use Disorder: A Guide For Emergency Nurses

Cook County See Record Opioid Deaths in Midst of Pandemic

Use Disorder and COVID-19: Crashing of the Crises

title: The COVID-19 Pandemic Continues to Challenge Patients In Need of Buprenorphine for Opioid Use Disorder The authors whose names are listed immediately below certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patentlicensing arrangements), or non-financial interest